(19)
(11) EP 3 638 225 A1

(12)

(43) Date of publication:
22.04.2020 Bulletin 2020/17

(21) Application number: 17734901.6

(22) Date of filing: 14.06.2017
(51) International Patent Classification (IPC): 
A61K 31/341(2006.01)
A61K 31/27(2006.01)
A61K 31/55(2006.01)
A61K 45/06(2006.01)
A61K 31/13(2006.01)
A61K 31/445(2006.01)
A61P 25/28(2006.01)
(86) International application number:
PCT/US2017/037436
(87) International publication number:
WO 2018/231216 (20.12.2018 Gazette 2018/51)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(71) Applicant: Anavex Life Sciences Corp.
New York, NY 10019 (US)

(72) Inventor:
  • CECCHI, Marco
    Louisville, KY 40204 (US)

(74) Representative: Sonn & Partner Patentanwälte 
Riemergasse 14
1010 Wien
1010 Wien (AT)

   


(54) ANAVEX2-73 FOR THE TREATMENT OF ALZHEIMER'S DISEASE